June 25, 2020 To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines.The academic sector plays an important role in […]
Read MoreJune 25, 2020 To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines.The academic sector plays an important role in […]
Read MoreJune 23rd 2020 The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2021 – FY 2022 […]
Read MoreJune 23rd 2020 The Food and Drug Administration
Read MoreJune 2, 2020 THE CALL IS CLOSED Share your expertise with IRDiRC The Consortium is seeking experts to join its Diagnostics Scientific Committee to work together to the achievement of IRDiRC Goal 1 for 2027: All […]
Read MoreJune 2, 2020 THE CALL IS CLOSED Share your expertise with IRDiRC The Consortium is seeking experts to join its Diagnostics Scientific Committee to work together to the achievement of IRDiRC Goal 1 for 2027: All […]
Read MoreMay 27, 2020 The commentary
Read MoreMay 27, 2020 The commentary ‘Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook’ has been published in Nature Reviews – Drug Discovery. This guidebook, which has […]
Read MoreEuropean Commission, EMA and FDA agree new priorities to strengthen their collaboration on medicines
June 26, 2020 Senior officials from the European Commission (EC – DG SANTE), EMA and the United States Food and Drug Administration (FDA) held their 2020 bilateral regulatory dialogue meeting. […]
Read MoreEuropean Commission, EMA and FDA agree new priorities to strengthen their collaboration on medicines
June 26, 2020 Senior officials from the European Commission (EC – DG SANTE), EMA and the United States Food and Drug Administration (FDA) held their 2020 bilateral regulatory dialogue meeting. […]
Read More